Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19.
Saved in:
| Title: | Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19. |
|---|---|
| Authors: | Prentice RE; Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, VIC, Australia., Tjandra D; Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, VIC, Australia., Garg M; Department of Gastroenterology, Northern Hospital and University of Melbourne, Melbourne, VIC, Australia., Lubel JS; Department of Gastroenterology, Alfred Hospital and Monash University, Melbourne, VIC, Australia., Fourlanos S; Department of Diabetes and Endocrinology, The Royal Melbourne Hospital, Melbourne, VIC, Australia., Johnson D; Victorian Infectious Diseases Unit, The Royal Melbourne Hospital, Melbourne, VIC, Australia., Al-Ani A; Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, VIC, Australia., Christensen B; Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, VIC, Australia. |
| Source: | Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2020 Oct; Vol. 52 (8), pp. 1422-1423. |
| Publication Type: | Letter; Comment |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
